tirzepatide · Eli Lilly
What should I know about Tirzepatide?
Tirzepatide by Eli Lilly: The molecule behind Mounjaro and Zepbound. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
GLP-1 culture
Cost
Cheapest Way to Get Tirzepatide Legally: 2026 PricesThe cheapest legal route depends on coverage: $25 for up to 3 months with a commercial plan that covers the drug, $50 per month through Medicare's GLP-1 Bridge starting July 1, 2026, near-zero on Medicaid in 13 states, or $299–$449 per month self-pay for the Zepbound KwikPen or vial.Does Medicare Cover Zepbound? Routes, Costs, and the $50 BridgeMedicare won't pay for Zepbound or Mounjaro for weight loss alone. Two routes exist: the GLP-1 Bridge at $50 per month (July 1, 2026–December 31, 2027, Zepbound KwikPen only) and regular Part D coverage for diabetes, sleep apnea, or fatty liver disease. Without coverage, the manufacturer discount price is $299.00.
Stopping and switching
Compounded
Compounded Tirzepatide vs Zepbound: Cost and DifferencesCompounded tirzepatide was reported as low as $99 a month in 2025, but no audited current prices exist. Zepbound self-pay starts at $299–$449 a month, and compounded versions are not reviewed by FDA for safety, effectiveness, or quality.Compounded Tirzepatide: What It Is and Whether It's Legal in 2026Compounded tirzepatide is a copy of the active ingredient in Mounjaro and Zepbound made by a pharmacy, not a generic and not FDA-reviewed. Mass compounding became unlawful after the FDA declared the shortage resolved on December 19, 2024, with enforcement deadlines passing in February and March 2025.How to Spot Fake Mounjaro or Zepbound: Warning Signs to CheckThe safest test is where it came from: Lilly is the only lawful supplier of FDA-approved tirzepatide and never sells on social media. FDA has received more than 730 adverse event reports tied to compounded tirzepatide, and one Tennessee raid seized more than 300 counterfeit vials.The Eli Lilly Lawsuit Over Compounded Tirzepatide: Who's Winning?Eli Lilly has sued compounding pharmacies, telehealth companies and importers over compounded tirzepatide since 2023. Courts have repeatedly rejected its federal false-advertising claims, but state claims are moving forward and the FDA's shortage delisting has been upheld.
Side effects
Does Zepbound Cause Hair Loss? What the Label and Studies ShowHair loss is a listed adverse reaction on the Zepbound label, reported by 4–5% of patients in trials versus 1% on placebo, mostly women, and the label ties it to weight reduction. Causality has not been established.Mounjaro Lawsuits: What's Alleged and Where Cases Stand in 2026Mounjaro is named in MDL 3094, the federal GLP-1 gastrointestinal injury litigation, and Zepbound is among Lilly's medicines at issue per its May 2026 brief. Nearly 3,000 gastroparesis suits were pending as of December 2025; a Daubert hearing was set for September 14–18, 2026.Mounjaro Side Effects: What the Label Reports and How OftenThe most common Mounjaro side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain; nausea reached 18% at the 15 mg dose in placebo-controlled trials. The label also carries a boxed warning about thyroid C-cell tumors seen in rats.Tirzepatide vs Semaglutide Side Effects: What Direct Comparison ShowsSURMOUNT-5 (751 adults) found mostly mild-to-moderate GI side effects in both arms; a 46,620-pair real-world study found an HR of 1.07 for serious GI events with tirzepatide vs semaglutide. Label percentages cannot be compared across drugs.Zepbound and Alcohol: Label Warnings and Drinking EvidenceThe Zepbound and Mounjaro Drug Interactions sections cover insulin, sulfonylureas, and oral medications. A study of more than 120 million US health records linked tirzepatide to about half the rate of new alcohol use disorder diagnoses (HR 0.47), and a 42-person randomized trial is underway.Zepbound Side Effects: Complete List of What Trials ShowIn the label's main safety pool of 2,519 adults, digestive problems dominate: 56% had a GI reaction on each Zepbound dose versus 30% on placebo, and 4.8% to 6.7% stopped treatment over side effects. The boxed warning covers thyroid C-cell tumors seen in rats, not proven in humans.
Results
Exercise on GLP-1 Drugs: What the Evidence Actually ShowsGLP-1 drugs produce major weight loss without supervised exercise, but roughly 25-39% of the weight lost is lean mass, versus 17.5% when lifestyle programs include resistance training. Exercise's clearest benefits show up in body composition and keeping weight off after the drug stops.GLP-1 Meal Plan Principles: What to Eat on Semaglutide or TirzepatideClinical reviews and dietitians give GLP-1 users the same core advice: smaller, more frequent meals with 20 to 30 grams of protein per meal, scheduled fluids, and gradual fiber, because 40% to 70% of patients get GI side effects. Here is what the guidance says, and what 'GLP-1 friendly' on a package means.GLP-1 Plateau: Why Weight Loss Stalls on Wegovy and ZepboundYes — a stall is a normal part of treatment. In tirzepatide trials, the median time to a weight plateau was 24.3 to 36.1 weeks depending on starting BMI, and about 90% of participants had plateaued by week 72.How Fast Does Zepbound Work? Timeline of Weight Loss ResultsZepbound's biggest share of loss came in the first 24 weeks — about 13.3% to 14.5% among adherent trial participants who lost at least 5% — with a plateau typically at 24 to 36 weeks and 72-week label averages of 15.0% to 20.9% depending on dose.How Much Protein on a GLP-1: What Published Targets SayPublished sources suggest roughly 1.0–1.5 g of protein per kg of body weight per day, or 80–120 g total, for adults losing weight on semaglutide or tirzepatide, with about 20–30 g per meal plus resistance training to help preserve muscle.
Who they're for
GLP-1 After Bariatric Surgery: Does It Work for Weight Regain?Yes — the evidence says it can work. In a 68-week randomized trial, semaglutide 2.4 mg once weekly produced −18.0% body weight versus +0.4% on placebo in people with poor results after gastric bypass or sleeve, with no new safety concerns. No GLP-1 is FDA-approved specifically for post-bariatric use.GLP-1 and Men's Health: Testosterone, Erections, Sperm and MusclePost hoc analyses reported in a conference abstract suggest women lose about 40% more weight than men on GLP-1 drugs. A review of five trials found no negative impact on hormones, sexual function or sperm quality, with possible testosterone gains for men whose low T is driven by obesity [1][10].GLP-1 and Menopause: Weight Loss Evidence and Hormone Therapy EffectsGLP-1 drugs still produce strong weight loss after menopause: tirzepatide cut body weight 23% vs 3% placebo in postmenopausal women, and the STEP pool showed a median −16.4% for semaglutide. Hormone therapy is linked to more loss (16% vs 12% at 12 months), but no trial proves it causes the difference.GLP-1 Over 65: What the Labels, Trials and Medicare Rules ShowNo GLP-1 label sets an upper age limit, and pooled trials find efficacy and safety in adults 65 and older broadly comparable to younger adults, though side effects force stopping more often after 65. Medicare's GLP-1 Bridge covers certain drugs for $50 a month from July 1, 2026 through December 31, 2027.
How it works
How Does Mounjaro Work? Mechanism, Dosing, and Ozempic ComparisonMounjaro (tirzepatide) is a once-weekly injection that activates two gut-hormone receptors, GIP and GLP-1, while drugs like Ozempic act on GLP-1 alone. Through GLP-1 signaling it stimulates insulin release, suppresses glucagon, slows the stomach, and cuts appetite; its half-life is about 5 days.How Does Zepbound Work? GIP and GLP-1, Explained SimplyZepbound (tirzepatide) activates two gut-hormone receptors at once, GIP and GLP-1, which is why it is called a dual agonist. It starts at 2.5 mg once weekly for 4 weeks and can go up to a 15 mg weekly maintenance dose.How Long Does Tirzepatide Stay in Your System? (Mounjaro, Zepbound)Tirzepatide has a half-life of about 5 days, so after your last weekly shot the drug keeps working its way out of your blood for roughly 25 days — about five half-lives. Here's what the labels and FDA review actually say.Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide (Mounjaro) targets two. In the only head-to-head trial, tirzepatide produced −20.2% body weight vs −13.7% for semaglutide at 72 weeks.Tirzepatide and Birth Control: Does It Affect the Pill?Yes — the Mounjaro and Zepbound labels say tirzepatide can affect absorption of oral contraceptives, and advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.What Is GIP? The Second Incretin Behind TirzepatideGIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that, like GLP-1, triggers insulin release after meals. Tirzepatide activates both receptors and beat semaglutide in trials; in a Phase 1b trial in type 2 diabetes, a GIP-only drug raised insulin sensitivity 33.1% over 12 weeks.
Trial evidence
How Much Weight Do You Lose on Zepbound? Trial Results by DoseIn the main 72-week trial, adults without diabetes lost an average of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg of Zepbound, versus 3.1% on placebo. Losses ran smaller with type 2 diabetes and in real-world data.Semaglutide vs Tirzepatide: Which Is Better for Weight Loss? SURMOUNT-5 ExplainedIn the first published head-to-head randomized trial in adults with obesity without diabetes, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. Here is what the study showed, plus side effects, heart evidence, and how clinicians say to choose.SURPASS-CVOT Results: What Tirzepatide Did for the Heart, ExplainedSURPASS-CVOT found tirzepatide (Mounjaro) noninferior to dulaglutide (Trulicity) for cardiovascular death, heart attack, or stroke: HR 0.92; 95.3% CI 0.83 to 1.01. Superiority was not met. A 16% lower all-cause death rate and kidney benefits were favorable but not statistically protected findings.Tirzepatide Clinical Trial Results: What the Studies ShowIn phase 3 trials, tirzepatide produced 15.0–20.9% mean weight loss over 72 weeks in adults with obesity (vs 3.1% on placebo) and cut HbA1c by 1.87–2.8 points across the diabetes trials, beating semaglutide 1 mg and two insulins head to head. Heart, kidney, and liver trial results were not verified for this page.What Happens If I Stop Taking Zepbound? What the Trials ShowIn the SURMOUNT-4 withdrawal trial, people who stopped tirzepatide regained an average of 14.0% of body weight in 52 weeks, while those who continued lost another 5.5%. Only 16.6% of stoppers kept most of their loss.
FDA and regulation
Is Compounded Tirzepatide Legal in 2026? What FDA Rules SayNo. Mass compounding of tirzepatide became unlawful after FDA resolved the shortage in December 2024 and grace periods closed in 2025. Only narrow 503A exceptions remain, and FDA has received more than 730 adverse event reports for compounded tirzepatide.Is Semaglutide Still in Shortage? FDA Status for 2026No. FDA declared the semaglutide injection shortage resolved on February 21, 2025, and an FDA statement dated April 1, 2026 confirms Ozempic and Wegovy are off the drug shortage list. Local pharmacy stock-outs can still happen.Is Tirzepatide Still in Shortage? FDA Status and TimelineNo. Tirzepatide injection (Mounjaro, Zepbound) came off the FDA drug shortage list on October 2, 2024, and FDA re-confirmed that decision on December 19, 2024. An appeals court upheld the removal on August 27, 2026.Tirzepatide Approvals by Country: Mounjaro and Zepbound WorldwideTirzepatide is approved for type 2 diabetes and weight management in the US, EU, UK, Canada, Australia, Japan, China and India. The US approved Mounjaro for diabetes on May 13, 2022 and sells the weight-loss version as Zepbound; the UK and Europe use the Mounjaro name for both uses.Tirzepatide FDA Approval History: Mounjaro and Zepbound, Year by YearThe FDA approved tirzepatide as Mounjaro (NDA 215866) on May 13, 2022 for type 2 diabetes and as Zepbound (NDA 217806) on November 8, 2023 for weight management. Later approvals added sleep apnea (December 20, 2024), pediatric diabetes (December 19, 2025), and cardiovascular risk reduction (August 27, 2026).
Emerging uses
Microdosing Zepbound: What the Evidence Actually ShowsMicrodosing Zepbound has no clinical definition, and clinicians say there is no robust evidence it works at very small doses. The label approves 5, 10, or 15 mg weekly for maintenance, and SURMOUNT-MAINTAIN found 5 mg held weight loss at −16.6% versus −9.9% for placebo.Tirzepatide and Heart Failure: What the SUMMIT Trial ShowedIn the SUMMIT trial, tirzepatide cut the combined risk of cardiovascular death or worsening heart failure by 38% (HR 0.62) in adults with HFpEF and obesity, but neither Zepbound nor Mounjaro is approved for heart failure in the US or EU.Tirzepatide for PCOS: Evidence, Approval, and Pregnancy RisksTirzepatide (Mounjaro/Zepbound) is not FDA-approved for PCOS. One small 16-week trial found 10.4 kg weight loss and 53.6% menstrual recovery when added to metformin, but a larger placebo-controlled trial is still recruiting.What Else Can Tirzepatide Treat? Approved and Studied UsesTirzepatide (Mounjaro, Zepbound) is FDA-approved for type 2 diabetes, weight loss, sleep apnea, and — since August 2026 — reducing heart attack and stroke risk in adults with diabetes at high risk. Heart failure, diabetes prevention, and fatty liver show positive trials but no approval.Zepbound for Sleep Apnea: What the Evidence Actually ShowsZepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. In 52-week trials it cut AHI by about 20-24 events per hour versus placebo, but sleep medicine groups say it is a tool alongside CPAP, not a replacement.
Common questions
Medications
Alternatives
Drug pipeline
Retatrutide: Weight Loss Results, Side Effects, and When It Could Be ApprovedRetatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1, glucagon). In the Phase 3 TRIUMPH-1 trial, the 12 mg dose produced 28.3% (70.3 lbs) average weight loss at 80 weeks. Lilly plans to file for FDA approval in Q1 2027.When Will Generic Ozempic Be Available in the US?No FDA-approved generic Ozempic exists as of August 2026, and experts do not expect one in the US until at least the end of 2031. India and Canada already have approved generics; the advocacy group I-MAK projects US patents could block entry as far out as 2042.